Jeg har kigget paa virksomheder med kraftig positiv (og negativ) vaekst i Q1 og/eller Q2. En af dem er Horizon Therapeutics. Markedsvaerdien er 15-16 milliarder dollar, saa maaske er foelgende interessant for nogle.
Jeg kan forresten se, at brugeren Bulder spurgte til PDUFA-datoen for Tepezza® (Teprotumumab) tilbage i November i chatten med Genmab, saa det kan betale sig at deltage i og foelge disse Q&A-sessions, hvis man er biotek/farma-investor.
https://www.proinvestor.com/uploads/ir/cms/QA-Genmab%202019-08-20.pdf
2020-08-05
Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EBITDA Guidance
https://www.businesswire.com/news/home/20200805005499/en/Horizon-Therapeutics-plc-Reports-Record-Second-Quarter-2020
-- Increasing TEPEZZA Peak U.S. Annual Net Sales Estimate to Greater Than $3 Billion from Greater Than $1 Billion --
2020-01-23
Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
https://ir.genmab.com/news-releases/news-release-details/horizon-therapeutics-secures-us-fda-approval-teprotumumab
2020-01-22
FDA approves former Genmab drug - royalties to follow
https://medwatch.dk/Top_picks_in_english/article11892752.ece
The US health authority, the FDA, has approved Horizon Therapeutics' eye medicine teprotumumab, which may earn Genmab a significant amount in royalties.
2020-01-21
FDA approves first treatment for thyroid eye disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). Today's approval represents the first drug approved for the treatment of thyroid eye disease.
Horizon 10K:
https://www.sec.gov/Archives/edgar/data/1492426/000156459020006575/hznp-10k_20191231.htm
The agreement with Roche also includes pay tiered royalties on annual worldwide net sales between 9 and 12 percent.
Gross profit:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.GrossProfit__.png
Operating income:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.OperatingIncomeLoss__.png
Retained earnings:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.RetainedEarningsAccumulatedDeficit__.png
Jeg kan forresten se, at brugeren Bulder spurgte til PDUFA-datoen for Tepezza® (Teprotumumab) tilbage i November i chatten med Genmab, saa det kan betale sig at deltage i og foelge disse Q&A-sessions, hvis man er biotek/farma-investor.
https://www.proinvestor.com/uploads/ir/cms/QA-Genmab%202019-08-20.pdf
2020-08-05
Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EBITDA Guidance
https://www.businesswire.com/news/home/20200805005499/en/Horizon-Therapeutics-plc-Reports-Record-Second-Quarter-2020
-- Increasing TEPEZZA Peak U.S. Annual Net Sales Estimate to Greater Than $3 Billion from Greater Than $1 Billion --
2020-01-23
Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
https://ir.genmab.com/news-releases/news-release-details/horizon-therapeutics-secures-us-fda-approval-teprotumumab
2020-01-22
FDA approves former Genmab drug - royalties to follow
https://medwatch.dk/Top_picks_in_english/article11892752.ece
The US health authority, the FDA, has approved Horizon Therapeutics' eye medicine teprotumumab, which may earn Genmab a significant amount in royalties.
2020-01-21
FDA approves first treatment for thyroid eye disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). Today's approval represents the first drug approved for the treatment of thyroid eye disease.
Horizon 10K:
https://www.sec.gov/Archives/edgar/data/1492426/000156459020006575/hznp-10k_20191231.htm
The agreement with Roche also includes pay tiered royalties on annual worldwide net sales between 9 and 12 percent.
Gross profit:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.GrossProfit__.png
Operating income:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.OperatingIncomeLoss__.png
Retained earnings:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.RetainedEarningsAccumulatedDeficit__.png
27/8 2020 19:16 tommycarstensen 1
86318 Jeg kunne ikke vedhaefte. Jeg proever igen. Naa, det virker ikke lige nu. Jeg ville vedhaefte denne figur, der viser Horizons salg for hvert af deres laegemidler:
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.RevenueFromContractWithCustomerExcludingAssessedTax_us-gaap.ProductOrService_.png
P.S. Jeg daar denne fejl:
Forbidden
You don't have permission to access this resource.
https://www.midgardfinance.com/10q10k/H/HZNP/HZNP_us-gaap.RevenueFromContractWithCustomerExcludingAssessedTax_us-gaap.ProductOrService_.png
P.S. Jeg daar denne fejl:
Forbidden
You don't have permission to access this resource.
